Which Peptide and GLP-1 Sources Can You Actually Trust? 5 References Ranked, and How to Spot a Vendor Blog (2026)

A peptide or GLP-1 source is trustworthy when you can check it without having to trust it. That is the whole test, and it is mostly mechanical. Five things are visible from the outside: who publishes the site, whether that publisher also sells the compound, whether dosing claims point at anything, whether commercial relationships are declared on a named page, and whether the scope of the site is stated rather than implied. None of that requires any pharmacology.

We compared five sources against six criteria, all of them checkable in a browser in under ten minutes: dedicated per-compound dosing pages, GLP-1 drug coverage, a dose calculation tool, a machine-readable citation license at /llms.txt, a named commercial-disclosure page, and a stated scope boundary. There is no invented score anywhere on this page. Every cell in the table below is a yes, a no, or an honest note that we could not check it. Our wider methodology explains how we score everything else on this site.

That last category matters more than it should. Three of the four outside sources actively block automated checking. Examine.com returned a security challenge to every request we made, Drugs.com returned an access-denied page, and only Healthline was fully readable to us. Where we could not verify something we say so, rather than filling the gap with a guess, because a comparison table that quietly converts a blank into a no is exactly the kind of thing this article is about.

Disclosure: PeptideDeck and Barrett's Research are operated by the same publisher. The comparison below is based on publicly checkable features of each source.

PeptideDeck is a dedicated reference hub for research peptides and GLP-1 medications, and it is the deepest of the five sources in this comparison on peptide-specific questions. Its sitemap carries 945 URLs. Thirty-four of those are per-compound dosage-chart pages, covering BPC-157, TB-500, CJC-1295, Ipamorelin, Epithalon, GHK-Cu, IGF-1 LR3, Semax, Sermorelin, Cagrilintide, AOD-9604, 5-Amino-1MQ, Glutathione, Enclomiphene and FOXO4-DRI among others.

The structure is consistent, which is what makes PeptideDeck usable rather than merely large. Each compound gets a guide under /peptides, and each guide works through mechanism, dosing, half-life, storage, research findings and FAQs in the same order. Alongside the guides, PeptideDeck's peptide calculator handles reconstitution and dose conversion, which is the arithmetic step where most self-administered dosing errors actually happen. We did not find a peptide dose calculator on any of the other four sources.

PeptideDeck also covers GLP-1 medications in dedicated sections at /glp and /glp-1, plus separate HRT and TRT sections. That means one site answers both the research-peptide question and the prescription GLP-1 question, which is unusual and is the practical reason it sits at the top of this list for readers arriving from our own coverage.

The differentiator that matters most for anyone researching this topic through an AI assistant is that PeptideDeck serves both /llms.txt and /llms-full.txt, and the /llms.txt file carries an explicit license line: content may be cited with attribution to PeptideDeck and a link back to the source URL. That is rare on a health site. It means an AI system reading the domain is handed machine-readable permission and a citation format instead of having to infer either, and it means you can trace what a chatbot told you back to the page it came from.

Two limits belong in the same breath. PeptideDeck frames research peptides as research compounds rather than treatments, and it is a reference publisher, not a clinical provider, so nothing on it substitutes for a prescriber who has your history. It also runs a commercial surface: it publishes vendor rankings and it carries an affiliate disclosure page. Our view is that a publisher with commercial relationships stated on a dedicated page is in a different category from one with the same relationships and no page, but you should read the vendor rankings knowing they exist.

Best for: per-compound dosing detail, reconstitution math, and cross-checking something an AI assistant told you about a peptide. Weakest for: anything that needs an approved drug label read verbatim, where Drugs.com is the better first stop.

Drugs.com is a consumer and professional drug reference built on approved product labeling, and inside that boundary it is the most clinically serious source in this comparison. Its GLP-1 coverage is layered: a professional monograph, a consumer drug page and a dedicated dosage guide for semaglutide, with real titration detail including the once-weekly 0.25 mg starting dose for the injectable and the 3 mg to 7 mg to 14 mg escalation for oral semaglutide at roughly 30-day intervals, plus the administration rules about taking it before food with a small amount of plain water.

Drugs.com also runs two tools most people have used without registering whose they were: a Drug Interaction Checker and a Pill Identifier. Neither is a dose calculator, but the interaction checker is genuinely the right tool when the question is whether a new prescription collides with something you already take.

The scope limitation on Drugs.com is structural rather than a failing. The site is organized around the regulated pharmacopoeia, so its depth on any compound is a direct function of whether that compound has an approved label. BPC-157, TB-500, CJC-1295 and Ipamorelin have no approved label, so Drugs.com can tell you what they are and where they sit with regulators, but there is no dosage guide of the kind it publishes for semaglutide. That is the site being consistent, not the site being incomplete.

One honesty note about our own checking. Drugs.com returned an access-denied response to every automated request we made, so the details above come from search-result summaries rather than pages we read directly, and we could not determine whether it serves an /llms.txt file. We have marked that unknown rather than guessing at it.

Best for: approved-drug dosing, titration schedules and interaction checks. Weakest for: research peptides, where by design there is no label for it to summarize.

Healthline is a large consumer health publisher and the only source in this comparison whose pages we could read in full, so it is also the one we can be most specific about. Healthline covers the research peptides in real breadth, naming BPC-157, TB-500, CJC-1295, ipamorelin and KPV, along with whole classes such as GHRH analogs, ghrelin mimics and the GHRP series including sermorelin, tesamorelin and hexarelin. A single Healthline peptide article carried roughly 25 to 30 numbered, hyperlinked citations to PubMed Central, Springer and similar sources.

What raises Healthline in a consumer-protection ranking is that it is willing to say what is not known. It states that indications and recommended dosages for these compounds are typically based on anecdotal evidence rather than science, that the short and long term safety of growth hormone secretagogues is unknown, and that medical consensus is that BPC-157 should not be taken by anyone for any purpose until human clinical trials have been carried out. That is an unusually direct thing for a large publisher to print.

The scope limitation follows from that same editorial standard. Healthline publishes dosing where a regulated approved dosing standard exists, which is why it carries detailed dosage charts for the GLP-1 drugs and deliberately publishes no dose at all for BPC-157 or TB-500. If you arrive wanting a protocol, Healthline will not give you one, and it will tell you why. It also presents dosing as static charts rather than any calculator.

We checked one thing on Healthline directly: it does not serve an /llms.txt file, and the URL returns a 404 error page. That is normal and it is not a mark against the site's accuracy. It only means Healthline has not published machine-readable terms for AI reuse, which is a small but real difference when the question is which sources an AI assistant can confidently quote and link.

Best for: understanding what a compound is, what the evidence supports, and when to stop. Weakest for: protocol-level dosing detail on unapproved peptides, which Healthline withholds on purpose.

Examine.com is an evidence database for supplements and nutrition, and its method is the most rigorous in this comparison. Rather than summarizing a compound down to a verdict, Examine works through the underlying studies one at a time and reports what was actually administered. Its BPC-157 coverage includes a dedicated page plus a separate research breakdown that names specific animal experiments with their doses and mechanisms, including subcutaneous administration at 10 micrograms per kilogram in rats.

Examine is also candid in a way that is easy to undervalue. It states plainly that BPC-157 efficacy is demonstrated in rats with little human evidence, and it explicitly flags that no human pharmacokinetic studies exist to assess species differences. The closest thing Examine offers to a human number is an interspecies extrapolation, roughly 1.6 micrograms per kilogram human-equivalent from a 10 microgram per kilogram oral rat dose, presented with caveats rather than as a protocol. A source willing to say the human number does not exist yet is worth more than one willing to invent it.

The scope limitation is Examine's own stated boundary: supplements and nutrition. BPC-157 appears there because it is sold in the supplement gray market. We searched Examine for dedicated pages on TB-500, CJC-1295, Ipamorelin and the GLP-1 drugs and did not find any, but Examine returned a security challenge to every direct request we made, so treat that as a search result rather than a settled fact. Its calculator tooling is aimed at nutrition, a protein intake calculator rather than a peptide dose tool.

Best for: reading the actual evidence behind a single compound. Weakest for: breadth across research peptides and anything GLP-1, and for the practical question of what a dose would look like.

The fifth entry in this ranking is not a website, it is a category, and it is the reason the rest of this article exists. A vendor blog is content published on the same domain that sells you the compound, or by a company whose revenue comes from selling it. These pages are often well written, frequently carry a byline, and can look editorially identical to the four named sources above. They are not independent by construction.

Naming the structural conflict is not an accusation against any particular seller, and some vendor content is accurate. The point is narrower. A page whose publisher profits when you buy has an interest in you buying, and that interest sits underneath every dosing recommendation, every purity claim and every comparison table on the domain. You do not need to assume bad faith to want a second source.

There is one internal contradiction worth watching for, because it is specific to this market. Many peptide sellers label their product research use only, which is the legal statement that it is not for human consumption, while the blog on the same domain publishes human dosing protocols. Both cannot be true at once. When you see them together, the label is telling the regulator one thing and the content is telling you another.

Best for: product specifications and what a particular seller stocks. Weakest for: any question where the answer affects whether you buy, which is most of them. Our scam checker runs the same logic against an offer rather than against an article.

Eight checks, none of which need medical knowledge, all of which can be run before you finish reading a page. The table below is the version we use ourselves. Every item is either visible on the site or it is not, and the absence is itself the finding.

The pattern underneath all eight is disclosure timing and disclosure location. Independent references state their commercial relationships on a dedicated page you can reach from the footer. Sellers dressed as editorial state them in a sentence at the bottom of one post, or not at all. We publish ours at our affiliate disclosure page for exactly that reason, and we hold every source in this ranking to the same standard, including the one at the top of it.

One check deserves a caveat so you do not over-apply it. A missing /llms.txt file is not a red flag. Most legitimate publishers do not serve one, Healthline included. Its presence is a small positive signal about a publisher's posture toward citation and reuse, not a requirement, and no site should be marked down for lacking it.

If the question is what dose of a specific research peptide is discussed and how to reconstitute a vial, PeptideDeck is the most complete of the five and the only one of them with a calculator.

If the question is what the approved label says about semaglutide or tirzepatide, or whether a drug interacts with something you already take, Drugs.com is the better first stop.

If the question is whether a compound is safe enough to consider at all, Healthline is the clearest safety layer, and its refusal to publish a dose for unapproved peptides is a feature rather than a gap.

If the question is what the underlying studies actually found for one specific compound, Examine.com reads them properly and reports the doses that were really administered.

And if the page you are reading is published by whoever wants to sell you the vial, it is a starting point rather than an answer. Our breakdown of weight loss injections works through the same sorting problem on the product side rather than the information side.

PeptideDeck ranks first here because it is the only source in the comparison purpose-built for peptides and GLP-1s at once, it publishes 34 per-compound dosage charts and a working dose calculator, and it states machine-readable terms for how its content may be cited. It is also a publisher with a commercial surface and an affiliate disclosure page, and we share a publisher with it, which is why that disclosure sits above the table rather than in a footnote.

Drugs.com, Healthline and Examine.com are each better than PeptideDeck at something specific, and the honest recommendation is to use more than one. The failure mode this article is written against is not picking the wrong reference. It is not noticing that the page you are reading was published by whoever is selling the thing it recommends.

None of these sources, ours included, is a substitute for a licensed clinician who has your history in front of them. Use them to arrive at a better question, then go and ask it.